Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455826 · ClinicalTrials.gov registry record · Phase 1
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
A Phase 1 study of Eye Diseases and Retinal Disease, sponsored by PYC Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 5
- Study locations
NCT06455826 is a Phase 1 study of Eye Diseases and Retinal Disease that is actively recruiting participants, run by PYC Therapeutics. The registered enrollment target is 12 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06455826, a Phase 1 study of Eye Diseases and Retinal Disease, is actively recruiting participants, sponsored by PYC Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Conditions Studied
Interventions
- DRUG VP-001
Study Locations (5)
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor College of Medicine- Alkek Eye Center - Houston
Florida
- University of Florida Health - Jacksonville
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Oregon
- Oregon Health and Science University - Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06455826
The ClinicalTrials.gov registry entry for NCT06455826 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is PYC Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Eye Diseases appearing as the primary indexed condition, and to 1 intervention - of which VP-001 is the first listed.
NCT06455826 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06455826 about?
NCT06455826 is a clinical study titled "MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)". A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
What is the current status of trial NCT06455826?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-13. Estimated completion is 2025-11.
What conditions does trial NCT06455826 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Retinal Degeneration, Retinal Dystrophies, Retinitis Pigmentosa 11.
What interventions are being tested in trial NCT06455826?
The interventions under investigation include: VP-001 (DRUG).
Who is sponsoring clinical trial NCT06455826?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455826 being conducted?
This trial has 5 study locations across Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ACTIVE NOT RECRUITING · Phase 1
-
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
COMPLETED · Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.